Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Prevalence of Hepatitis in Prisoners: A Systematic Review of Current Evidence

Author(s): Salar Pashangzadeh, SeyedAhmad SeyedAlinaghi, Omid Dadras, Zahra Pashaei, Mahdi Soleymanzadeh, Alireza Barzegary, Pegah Mirzapour, Farzin Vahedi, Amirata Fakhfouri, Tayebeh Noori, Seyed Mohammad Hossein Irani, Esmaeil Mehraeen* and Shayesteh Jahanfar

Volume 22, Issue 8, 2022

Published on: 15 August, 2022

Article ID: e200622206190 Pages: 12

DOI: 10.2174/1871526522666220620115006

Price: $65

Abstract

Introduction: Prisoners represent high-risk behaviors such as injecting drug use, sharing syringes, tattooing, and unprotected sexual intercourse. The authors aimed to study the prevalence of hepatitis B, hepatitis C, and hepatitis D in the prisoners.

Methods: We conducted a systematic search using the keywords in online databases of PubMed, Web of Science, Scopus, and Science Direct. Two independent researchers examined the quality of the articles and the probable risk of bias. The most relevant articles by title and abstract were retrieved. Finally, the full text of selected articles was read, and the critical findings were extracted.

Results: Reviews of 23 studies showed that most prisoners are susceptible to hepatitis B and hepatitis C. One study also indicated that prisoners could be infected with hepatitis A and hepatitis E. The most common routes of hepatitis transmission in prisons were intravenous drug use, needle sharing, tattooing, and unsafe sex with multiple sexual partners.

Conclusion: High-risk sexual behaviors, shared contaminated needles for IV drug injection, and tattooing are the principal routes of hepatitis transmission among prison inmates. Hepatitis treatment is feasible and could be useful for infected prisoners undergoing a well-designed treatment program.

Keywords: Hepatitis B, hepatitis C, hepatitis D, prisoners, injecting drug, liver disease.

Graphical Abstract

[1]
Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N Engl J Med 2012; 366(5): 454-61.
[http://dx.doi.org/10.1056/NEJMra1108296] [PMID: 22296079]
[2]
Ale-Ebrahim J, Janani L, Seyed ASA, et al. Patterns of high-risk behaviors associated with HIV among male prisoners: A latent class analysis. Med J Islam Repub Iran 2020; 34: 109.
[http://dx.doi.org/10.47176/mjiri.34.109] [PMID: 33316009]
[3]
Global hepatitis report. 2017. Available from: https://www.who. int/hepatitis/publications/global-hepatitis-report2017/en/
[4]
Najafi Z, Taj L, Dadras O, Ghadimi F, Moradmand B, Seyed AS. Epidemiology of HIV in Iran. Curr HIV Res 2020; 18(4): 228-36.
[http://dx.doi.org/10.2174/1570162X18666200605152317] [PMID: 32503409]
[5]
Hepatitis B. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
[6]
Firouzeh MM, Moradbeigi M, Seyed ASA, et al. Demographic, clinical and laboratory profiles of HIV infected patients admitted into imam khomeini hospital of Tehran, Iran. Infect Disord Drug Targets 2016; 16(2): 113-20.
[http://dx.doi.org/10.2174/1871526516666151230115809] [PMID: 26715444]
[7]
Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol Hepatol 2018; 3(6): 383-403.
[http://dx.doi.org/10.1016/S2468-1253(18)30056-6] [PMID: 29599078]
[8]
Seyed ASA, Kheirandish P, Karami N, et al. High prevalence of chronic hepatitis B infection among injection drug users in Iran: The need to increase vaccination of adults at risk. Acta Med Iran 2010; 48(1): 58-60.
[PMID: 21137671]
[9]
Seyed AS, Jam S, Mehrkhani F, et al. Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. Acta Med Iran 2011; 49(4): 252-7.
[PMID: 21713737]
[10]
Hosseini M, SeyedAlinaghi S, Kheirandish P, et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med 2010; 13(4): 318-23.
[PMID: 20597566]
[11]
Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J Hepatol 2016; 64(1): S102-16.
[http://dx.doi.org/10.1016/j.jhep.2016.02.013] [PMID: 27084031]
[12]
Sarvari J, Mojtahedi Z, Taghavi SAR, et al. Differentially expressed proteins in chronic active hepatitis, cirrhosis, and HCC related to HCV infection in comparison with HBV infection: A proteomics study. Hepat Mon 2013; 13(7): e8351.
[http://dx.doi.org/10.5812/hepatmon.8351] [PMID: 24066001]
[13]
Kew MC. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: An update. J Viral Hepat 2013; 20(3): 149-57.
[http://dx.doi.org/10.1111/jvh.12043] [PMID: 23383653]
[14]
Mansha S, Imran M, Shah A, et al. Hepatitis B and C virus infections among human immunodeficiency virus-infected people who inject drugs in Lahore, Pakistan. Viral Immunol 2017; 30(5): 366-70.
[http://dx.doi.org/10.1089/vim.2016.0144] [PMID: 28346804]
[15]
Rahimi-Movaghar A, Amin-Esmaeili M, Haghdoost AA, Sadeghirad B, Mohraz M. HIV prevalence amongst injecting drug users in Iran: A systematic review of studies conducted during the decade 1998-2007. Int J Drug Policy 2012; 23(4): 271-8.
[http://dx.doi.org/10.1016/j.drugpo.2011.09.002] [PMID: 22000694]
[16]
Buchanan R, Khakoo SI, Coad J, Grellier L, Parkes J. Hepatitis C bio-behavioural surveys in people who inject drugs-a systematic review of sensitivity to the theoretical assumptions of respondent driven sampling. Harm Reduct J 2017; 14(1): 44.
[http://dx.doi.org/10.1186/s12954-017-0172-z] [PMID: 28697760]
[17]
Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV co-infection prevalence in Iran-a systematic review and meta-analysis. PLoS One 2016; 11(3): e0151946.
[http://dx.doi.org/10.1371/journal.pone.0151946] [PMID: 27031352]
[18]
Cross TJ, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80(2): 277-82.
[http://dx.doi.org/10.1002/jmv.21078] [PMID: 18098143]
[19]
Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis 2002; 35(3): 305-12.
[http://dx.doi.org/10.1086/341418] [PMID: 12115097]
[20]
Okafor IM, Ugwu SO, Okoroiwu HU. Hepatitis C virus infection and its associated factors among prisoners in a Nigerian prison. BMC Gastroenterol 2020; 20(1): 360.
[http://dx.doi.org/10.1186/s12876-020-01504-8] [PMID: 33126856]
[21]
Taylor A, Goldberg D, Hutchinson S, et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect 2000; 40(2): 176-83.
[http://dx.doi.org/10.1053/jinf.2000.0647] [PMID: 10841096]
[22]
Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997; 26(6): 1359-66.
[http://dx.doi.org/10.1093/ije/26.6.1359] [PMID: 9447418]
[23]
Hutchinson SJ, Goldberg DJ, Gore SM, et al. Hepatitis B outbreak at Glenochil prison during January to June 1993. Epidemiol Infect 1998; 121(1): 185-91.
[http://dx.doi.org/10.1017/S0950268898001022] [PMID: 9747771]
[24]
Vieira D, Oliveira S, Santos A. Prevalence of viral hepatitis B, C and Delta, syphilis and HIV in the prison population in the closed penal system of the western Amazon. J Bacteriol Infect Dis 2018; 2(2): 6-11.
[25]
Tucker RM, Gaffey MJ, Fisch MJ, Kaiser DL, Guerrant RL, Normansell DE. Seroepidemiology of hepatitis D (delta agent) and hepatitis B among Virginia State prisoners. Clin Ther 1987; 9(6): 622-8.
[PMID: 3440274]
[26]
Motamedifar M, Taheri M, Lankarani KB, et al. The prevalence and risk factors of hepatitis delta virus in HIV/HBV co-infected patients in Shiraz, Iran, 2012. Iran J Med Sci 2015; 40(5): 448-53.
[PMID: 26379352]
[27]
Ali M, Idrees M, Ali L, et al. Hepatitis B virus in Pakistan: a systematic review of prevalence, risk factors, awareness status and genotypes. Virol J 2011; 8(1): 102.
[http://dx.doi.org/10.1186/1743-422X-8-102] [PMID: 21375760]
[28]
Chimphambano C, Komolafe I, Muula A. Prevalence of HIV, HepBsAg and Hep C antibodies among inmates in Chichiri prison, Blantyre, Malawi. Malawi Med J 2007; 19(3): 107-10.
[PMID: 23878651]
[29]
Wali A, Khan D, Safdar N, et al. Prevalence of tuberculosis, HIV/AIDS, and hepatitis; in a prison of Balochistan: a cross-sectional survey. BMC Public Health 2019; 19(1): 1631.
[http://dx.doi.org/10.1186/s12889-019-8011-7] [PMID: 31801496]
[30]
Jaquet A, Wandeler G, Tine J, et al. HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. BMC Infect Dis 2016; 16(1): 249.
[http://dx.doi.org/10.1186/s12879-016-1601-4] [PMID: 27267370]
[31]
Gahrton C, Westman G, Lindahl K, et al. Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infect Dis 2019; 19(1): 955.
[http://dx.doi.org/10.1186/s12879-019-4581-3] [PMID: 31706284]
[32]
Bayas JM, Bruguera M, Martín V, et al. Hepatitis B and hepatitis delta in young inmates. Med Clin 1990; 94(5): 164-8.
[PMID: 2325476]
[33]
Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep 2013; 15(1): 31-8.
[http://dx.doi.org/10.1007/s11908-012-0307-z] [PMID: 23242761]
[34]
Liver eaftsot. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370-98.
[http://dx.doi.org/10.1016/j.jhep.2017.03.021] [PMID: 28427875]
[35]
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017; 166(9): 637-48.
[http://dx.doi.org/10.7326/M16-2575] [PMID: 28319996]
[36]
Aspinall EJ, Mitchell W, Schofield J, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat 2016; 23(12): 1009-16.
[http://dx.doi.org/10.1111/jvh.12580] [PMID: 27509844]
[37]
Barros LA, Pessoni GC, Teles SA, et al. Epidemiology of the viral hepatitis B and C in female prisoners of Metropolitan Regional Prison Complex in the State of Goiás, Central Brazil. Rev Soc Bras Med Trop 2013; 46(1): 24-9.
[http://dx.doi.org/10.1590/0037-868216972013] [PMID: 23563821]
[38]
Belaunzaran-Zamudio PF, Mosqueda-Gomez JL, Macias-Hernandez A, Rodríguez-Ramírez S, Sierra-Madero J, Beyrer C. Burden of HIV, Syphilis, and hepatitis B and C among inmates in a prison state system in Mexico. AIDS Res Hum Retroviruses 2017; 33(6): 524-33.
[http://dx.doi.org/10.1089/aid.2016.0271] [PMID: 28094553]
[39]
Belaunzarán-Zamudio PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, Ahmed S, Beyrer C. Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico. PLoS One 2017; 12(6): e0179931.
[http://dx.doi.org/10.1371/journal.pone.0179931] [PMID: 28654650]
[40]
Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust 2010; 192(9): 496-500.
[http://dx.doi.org/10.5694/j.1326-5377.2010.tb03605.x] [PMID: 20438418]
[41]
Cunningham EB, Hajarizadeh B, Bretana NA, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study. J Viral Hepat 2017; 24(9): 733-41.
[http://dx.doi.org/10.1111/jvh.12701] [PMID: 28256027]
[42]
El Maerrawi I, Carvalho HB. Prevalence and risk factors associated with HIV infection, hepatitis and syphilis in a state prison of São Paulo. Int J STD AIDS 2015; 26(2): 120-7.
[http://dx.doi.org/10.1177/0956462414531242] [PMID: 24733152]
[43]
Getaz L, Casillas A, Motamed S, Gaspoz JM, Chappuis F, Wolff H. Hepatitis A immunity and region-of-origin in a Swiss prison. Int J Prison Health 2016; 12(2): 98-105.
[http://dx.doi.org/10.1108/IJPH-10-2015-0033] [PMID: 27219907]
[44]
Gétaz L, Casillas A, Siegrist CA, et al. Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland’s largest pre-trial prison. J Glob Health 2018; 8(2): 020407.
[http://dx.doi.org/10.7189/jogh.08.020407] [PMID: 30140433]
[45]
Hariri S, Sharafi H, Sheikh M, et al. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era. Harm Reduct J 2020; 17(1): 80.
[http://dx.doi.org/10.1186/s12954-020-00431-x] [PMID: 33081794]
[46]
Izquierdo L, Mellon G, Buchaillet C, et al. Prevalence of hepatitis E virus and reassessment of HIV and other hepatitis virus seroprevalences among French prison inmates. PLoS One 2019; 14(6): e0218482.
[http://dx.doi.org/10.1371/journal.pone.0218482] [PMID: 31242210]
[47]
Kassaian N, Adibi P, Kafashaian A, et al. Hepatitis C Virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran. Int J Prev Med 2012; 3: S156-61.
[PMID: 22826759]
[48]
Kronfli N, Dussault C, Klein MB, Lebouché B, Sebastiani G, Cox J. The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. CMAJ Open 2019; 7(4): E674-9.
[http://dx.doi.org/10.9778/cmajo.20190068] [PMID: 31796509]
[49]
Li H, Cameron B, Douglas D, et al. Incident Hepatitis B virus infection and immunisation uptake in Australian prison inmates. Vaccine 2020; 38(16): 3255-60.
[http://dx.doi.org/10.1016/j.vaccine.2020.02.076] [PMID: 32151462]
[50]
Nelwan EJ, Van Crevel R, Alisjahbana B, et al. Human immunodeficiency virus, Hepatitis B and Hepatitis C in an Indonesian prison: prevalence, risk factors and implications of HIV screening. Trop Med Int Health 2010; 15(12): 1491-8.
[http://dx.doi.org/10.1111/j.1365-3156.2010.02655.x] [PMID: 20955370]
[51]
Niriella MA, Hapangama A, Luke HP, Pathmeswaran A, Kuruppuarachchi KA, de Silva HJ. Prevalence of Hepatitis B and Hepatitis C infections and their relationship to injectable drug use in a cohort of Sri Lankan prison inmates. Ceylon Med J 2015; 60(1): 18-20.
[http://dx.doi.org/10.4038/cmj.v60i1.7288] [PMID: 25804913]
[52]
Stief AC, Martins RM, Andrade SM, et al. Seroprevalence of Hepatitis B virus infection and associated factors among prison inmates in state of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop 2010; 43(5): 512-5.
[http://dx.doi.org/10.1590/S0037-86822010000500008] [PMID: 21085860]
[53]
Treloar C, McCredie L, Lloyd AR. Acquiring hepatitis C in prison: the social organisation of injecting risk. Harm Reduct J 2015; 12: 10.
[http://dx.doi.org/10.1186/s12954-015-0045-2] [PMID: 25903401]
[54]
Villarroel-Torrico M, Montaño K, Flores-Arispe P, et al. Syphilis, human immunodeficiency virus, herpes genital and Hepatitis B in a women’s prison in Cochabamba, Bolivia: prevalence and risk factors. Rev Esp Sanid Penit 2018; 20(2): 47-54.
[PMID: 30231151]
[55]
Viswanathan U, Beaumont A, O’Moore E, et al. Hepatitis B transmission event in an English prison and the importance of immunization. J Public Health (Oxf) 2011; 33(2): 193-6.
[http://dx.doi.org/10.1093/pubmed/fdq083] [PMID: 20965882]
[56]
Adjei AA, Armah HB, Gbagbo F, et al. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana. J Med Microbiol 2006; 55(Pt 5): 593-7.
[http://dx.doi.org/10.1099/jmm.0.46414-0] [PMID: 16585647]
[57]
Mohammad AH, Alavian SM, Jafari K, Yazdi N. Prevalence of Hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol 2005; 11(26): 4085-9.
[http://dx.doi.org/10.3748/wjg.v11.i26.4085] [PMID: 15996035]
[58]
Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digest Liver Dis 2011; 43(8): 589-95.
[59]
Reekie JM, Levy MH, Richards AH, et al. Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010. Med J Aust 2014; 200(5): 277-80.
[http://dx.doi.org/10.5694/mja13.11062] [PMID: 24641153]
[60]
Prasetyo AA, Dirgahayu P, Sari Y, Hudiyono H, Kageyama S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. J Infect Dev Ctries 2013; 7(6): 453-67.
[http://dx.doi.org/10.3855/jidc.2965] [PMID: 23771289]
[61]
Alavian S, Fallahian F. Epidemiology of Hepatitis C in Iran and the World 2009; 10(4): 162-72.
[62]
Puga MA, Bandeira LM, Pompilio MA, et al. Prevalence and incidence of HCV Infection among Prisoners in Central Brazil. PLoS One 2017; 12(1): e0169195.
[http://dx.doi.org/10.1371/journal.pone.0169195] [PMID: 28060860]
[63]
Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(3): 62S-5S.
[http://dx.doi.org/10.1002/hep.510260711] [PMID: 9305666]
[64]
Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26(2): 171-84.
[http://dx.doi.org/10.1016/S1386-6532(02)00116-6]
[65]
Dolan K, Kite B, Black E, Aceijas C, Stimson GV. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007; 7(1): 32-41.
[http://dx.doi.org/10.1016/S1473-3099(06)70685-5] [PMID: 17182342]
[66]
Thaisri H, Lerwitworapong J, Vongsheree S, et al. HIV infection and risk factors among Bangkok prisoners, Thailand: a prospective cohort study. BMC Infect Dis 2003; 3: 25.
[http://dx.doi.org/10.1186/1471-2334-3-25] [PMID: 14580265]
[67]
Strazza L, Massad E, Azevedo RS, Carvalho HB. Behavior associated with HIV and HCV infection in female prison inmates in São Paulo, Brazil. Cad Saude Publica 2007; 23(1): 197-205.
[http://dx.doi.org/10.1590/S0102-311X2007000100021] [PMID: 17187118]
[68]
Sarang A, Rhodes T, Platt L, et al. Drug injecting and syringe use in the HIV risk environment of Russian penitentiary institutions: Qualitative study. Addiction 2006; 101(12): 1787-96.
[http://dx.doi.org/10.1111/j.1360-0443.2006.01617.x] [PMID: 17156178]
[69]
Taylor A, Goldberg D, Emslie J, et al. Outbreak of HIV infection in a Scottish prison. BMJ 1995; 310(6975): 289-92.
[http://dx.doi.org/10.1136/bmj.310.6975.289] [PMID: 7866169]
[70]
Kheirandish P, Seyedalinaghi SA, Hosseini M, Jahani MR, Shirzad H, Foroughi M. Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. J Acquir Immune Defic Syndromes 2010; 53(2): 273-5.
[71]
Mahanta J, Medhi GK, Paranjape RS, et al. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India. AIDS 2008; 22: S59-68.
[http://dx.doi.org/10.1097/01.aids.0000343764.62455.9e] [PMID: 19098480]
[72]
Maranda MJ, Han C, Rainone GA. Crack cocaine and sex. J Psychoactive Drugs 2004; 36(3): 315-22.
[http://dx.doi.org/10.1080/02791072.2004.10400032] [PMID: 15559679]
[73]
Alvarado-Esquivel C, Sablon E, Martínez-García S, Estrada-Martínez S. Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico. Epidemiol Infect 2005; 133(4): 679-85.
[http://dx.doi.org/10.1017/S0950268805003961] [PMID: 16050514]
[74]
Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons--not such a pretty picture. Am J Infect Control 2007; 35(7): 477-80.
[http://dx.doi.org/10.1016/j.ajic.2006.08.002] [PMID: 17765561]
[75]
Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001; 127(3): 475-84.
[http://dx.doi.org/10.1017/S0950268801006197] [PMID: 11811881]
[76]
Crofts N, Caruana S, Bowden S, Kerger M. Minimising harm from hepatitis C virus needs better strategies. BMJ 2000; 321(7265): 899.
[http://dx.doi.org/10.1136/bmj.321.7265.899] [PMID: 11021890]
[77]
Humphreys C, Railton C, O’Moore É, Lombard M, Newton A. An audit of hepatitis C service provision in a representative sample of prisons in England. J Public Health 2015; 37(1): 151-6.
[http://dx.doi.org/10.1093/pubmed/fdu022] [PMID: 24700887]
[78]
Akiyama MJ, Columbus D, MacDonald R, et al. Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial. BMC Infect Dis 2019; 19(1): 703.
[http://dx.doi.org/10.1186/s12879-019-4344-1] [PMID: 31395019]
[79]
Beckwith CG, Kurth AE, Bazerman LB, et al. A pilot study of rapid hepatitis C virus testing in the Rhode island department of corrections. J Public Health 2016; 38(1): 130-7.
[http://dx.doi.org/10.1093/pubmed/fdv023] [PMID: 25736438]
[80]
Schoenbachler BT, Smith BD, Seña AC, Hilton A, Bachman S, Lunda M. Hepatitis C Virus Testing and Linkage to Care in North Carolina and South Carolina Jails, 2012-2014. Public health reports (Washington, DC: 1974) 2016; 2(2): 98-104.
[81]
Kendall S, Redshaw S, Ward S, Wayland S, Sullivan E. Systematic review of qualitative evaluations of reentry programs addressing problematic drug use and mental health disorders amongst people transitioning from prison to communities. Health Justice 2018; 6(1): 4.
[http://dx.doi.org/10.1186/s40352-018-0063-8] [PMID: 29500640]
[82]
Majori S, Baldo V, Tommasi I, et al. Hepatitis A, B, and C infection in a community of sub-Saharan immigrants living in Verona (Italy). J Travel Med 2008; 15(5): 323-7.
[http://dx.doi.org/10.1111/j.1708-8305.2008.00230.x] [PMID: 19006505]
[83]
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386(10003): 1546-55.
[http://dx.doi.org/10.1016/S0140-6736(15)61412-X] [PMID: 26231459]
[84]
Durro V, Qyra S. Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999-2009. Virol J 2011; 8: 96.
[http://dx.doi.org/10.1186/1743-422X-8-96] [PMID: 21375724]
[85]
Hwang EW. Global epidemiology of hepatitis B virus (HBV) infection. 2011; 4(1)
[http://dx.doi.org/10.7156/V411P007] [PMID: 73232193]
[86]
Sbai A, Baha W, Ougabrai H, et al. Hepatitis B prevalence and risk factors in Morocco. Pathol Biol 2012; 60(5): e65-9.
[http://dx.doi.org/10.1016/j.patbio.2011.06.001] [PMID: 21816547]
[87]
Corona R, Caprilli F, Giglio A, et al. Risk factors for hepatitis B virus infection among heterosexuals attending a sexually transmitted diseases clinic in Italy: role of genital ulcerative diseases. J Med Virol 1996; 48(3): 262-6.
[http://dx.doi.org/10.1002/(SICI)1096-9071(199603)48:3<262::AID-JMV8>3.0.CO;2-6] [PMID: 8801287]
[88]
Ferreira RC, Rodrigues FP, Teles SA, et al. Prevalence of hepatitis B virus and risk factors in Brazilian non-injecting drug users. J Med Virol 2009; 81(4): 602-9.
[http://dx.doi.org/10.1002/jmv.21464] [PMID: 19235862]
[89]
Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franceschi S. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 2008; 80(1): 53-7.
[http://dx.doi.org/10.1002/jmv.21046] [PMID: 18041005]
[90]
Babudieri S, Longo B, Sarmati L, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol 2005; 76(3): 311-7.
[http://dx.doi.org/10.1002/jmv.20375] [PMID: 15902712]
[91]
Butler T, Boonwaat L, Hailstone S, et al. The 2004 Australian prison entrants’ blood-borne virus and risk behaviour survey. Aust N Z J Public Health 2007; 31(1): 44-50.
[http://dx.doi.org/10.1111/j.1753-6405.2007.00009.x] [PMID: 17333608]
[92]
Adjei AA, Armah HB, Gbagbo F, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study. BMC Infect Dis 2008; 8: 33.
[http://dx.doi.org/10.1186/1471-2334-8-33] [PMID: 18328097]
[93]
Adoga MP, Banwat EB, Forbi JC, et al. Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infect Dev Ctries 2009; 3(7): 539-47.
[http://dx.doi.org/10.3855/jidc.472] [PMID: 19762972]
[94]
Fretz R, Negro F, Bruggmann P, et al. Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Med Wkly 2013; 143: w13793.
[http://dx.doi.org/10.4414/smw.2013.13793] [PMID: 23740193]
[95]
Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147(7): 460-9.
[http://dx.doi.org/10.7326/0003-4819-147-7-200710020-00004] [PMID: 17909207]
[96]
Crofts N, Cooper G, Stewart T, et al. Exposure to hepatitis A virus among blood donors, injecting drug users and prison entrants in Victoria. J Viral Hepat 1997; 4(5): 333-8.
[http://dx.doi.org/10.1046/j.1365-2893.1997.00059.x] [PMID: 9310932]
[97]
Skidmore S, Parry JV, Nottage P. An investigation of the potential risk of an HAV outbreak in a prison population following the introduction of cases from a community outbreak. Commun Dis Public Health 2001; 4(2): 133-5.
[PMID: 11525002]
[98]
Whiteman D, McCall B. Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. 1998; 5(4): 277-83.
[99]
Holter E, Siebke JC. Hepatitis A in young Norwegian drug addicts and prison inmates. Infection 1988; 16(2): 91-4.
[http://dx.doi.org/10.1007/BF01644310] [PMID: 2836313]
[100]
Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports 2003; 52(1): 1-36.
[101]
Gondles EF. A call to immunize the correctional population for hepatitis A and B. Am J Med 2005; 118(10): 84S-9S.
[http://dx.doi.org/10.1016/j.amjmed.2005.07.025] [PMID: 16271547]
[102]
Roy K, Howie H, Sweeney C, et al. Hepatitis A virus and injecting drug misuse in Aberdeen, Scotland: a case-control study. J Viral Hepat 2004; 11(3): 277-82.
[http://dx.doi.org/10.1111/j.1365-2893.2004.00503.x] [PMID: 15117332]
[103]
Gétaz L, Siegrist CA, Stoll B, et al. Chickenpox in a Swiss prison: susceptibility, post-exposure vaccination and control measures. Scand J Infect Dis 2010; 42(11-12): 936-40.
[http://dx.doi.org/10.3109/00365548.2010.511259] [PMID: 20854218]
[104]
Meng XJ. Recent advances in Hepatitis E virus. J Viral Hepat 2010; 17(3): 153-61.
[http://dx.doi.org/10.1111/j.1365-2893.2009.01257.x] [PMID: 20040046]
[105]
Preiss JC, Plentz A, Engelmann E, et al. Autochthonous Hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection 2006; 34(3): 173-5.
[http://dx.doi.org/10.1007/s15010-006-4132-x] [PMID: 16804663]
[106]
Pfefferle S, Frickmann H, Gabriel M, Schmitz N, Günther S, Schmidt-Chanasit J. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection 2012; 40(4): 451-4.
[http://dx.doi.org/10.1007/s15010-011-0220-7] [PMID: 22086667]
[107]
Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S. Sporadic cases of acute autochthonous Hepatitis E virus infection in Southwest Germany. J Clin Virol 2010; 47(1): 89-92.
[http://dx.doi.org/10.1016/j.jcv.2009.10.011]
[108]
Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008; 48(3): 494-503.
[http://dx.doi.org/10.1016/j.jhep.2007.12.008] [PMID: 18192058]
[109]
Matsubayashi K, Kang JH, Sakata H, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 2008; 48(7): 1368-75.
[http://dx.doi.org/10.1111/j.1537-2995.2008.01722.x] [PMID: 18651907]
[110]
Romanò L, Paladini S, Tagliacarne C, Canuti M, Bianchi S, Zanetti AR. Hepatitis E in Italy: a long-term prospective study. J Hepatol 2011; 54(1): 34-40.
[http://dx.doi.org/10.1016/j.jhep.2010.06.017] [PMID: 20888660]
[111]
Zanetti AR, Dawson GJ. Hepatitis type E in Italy: a seroepidemiological survey. J Med Virol 1994; 42(3): 318-20.
[http://dx.doi.org/10.1002/jmv.1890420321] [PMID: 8006645]
[112]
Gessoni G, Manoni F. Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. J Viral Hepat 1996; 3(4): 197-202.
[http://dx.doi.org/10.1111/j.1365-2893.1996.tb00095.x] [PMID: 8871881]
[113]
Rapicetta M, Kondili LA, Pretolani S, et al. Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. J Med Virol 1999; 58(1): 49-53.
[http://dx.doi.org/10.1002/(SICI)1096-9071(199905)58:1<49:AID-JMV7>3.0.CO;2-C] [PMID: 10223545]
[114]
Mansuy JM, Gallian P, Dimeglio C, et al. A nationwide survey of hepatitis E viral infection in French blood donors. Hepatology 2016; 63(4): 1145-54.
[http://dx.doi.org/10.1002/hep.28436] [PMID: 27008201]
[115]
Rapicetta M, Monarca R, Kondili LA, et al. Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy. Infection 2013; 41(1): 69-76.
[http://dx.doi.org/10.1007/s15010-012-0385-8] [PMID: 23264095]
[116]
Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health 2009; 86(6): 902-8.
[http://dx.doi.org/10.1007/s11524-009-9393-0] [PMID: 19844670]
[117]
Farhoudi B. SeyedAlinaghi SA, Mohraz M, Hosseini M, Farnia M. Tuberculosis, hepatitis C and hepatitis B co-infections in patients with HIV in the Great Tehran Prison, Iran. Asian Pac J Trop Dis 2016; 6(1): 82-3.
[http://dx.doi.org/10.1016/S2222-1808(15)60989-6]
[118]
Farhoudi B, SeyedAlinaghi S, Dadras O, et al. Health service provision for disease control among prisoners: a conceptual note. J Health Res 2020; 34(4): 353-8.
[http://dx.doi.org/10.1108/JHR-04-2019-0068]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy